Cigna Corp. agreed to sell the health insurer’s disability and accidental death insurance unit for company employees to New York Life Insurance Co. in a $6.3 billion deal.

The Federal Trade Commission filed a complaint aimed at stopping Illumina Inc. from purchasing Pacific Biosciences of California.

Swiss pharma giant Roche’s 10-month journey to complete the acquisition of the gene therapy company Spark Therapeutics was finalized.

Correvio Pharma Corp. is exploring options including putting itself up for sale, a day after a panel of experts advising the U.S. health regulator voted against approving the company’s heart drug.

Merck & Co. Inc. is buying ArQule Inc. for $2.7 billion, seeking to tap into the drug developer’s experimental blood cancer therapy that targets genetic mutations.

U.S. Food and Drug Administration staffers reviewing Correvio Pharma Corp.’s Brinavess said they did not believe the benefits of the heart drug outweighed the therapy’s risks, sending the company’s shares down nearly 38 percent.

Tokyo-based Astellas Pharma announced plans to acquire San Francisco-based Audentes Therapeutics for $60 per share in cash, representing a total equity value of about $3 billion.

One week after announcing positive data from ORION-10, the second of three 19-month Phase III trials for inclisiran for lowering cholesterol, The Medicines Co. was acquired by Novartis.

Amgen filed a Worker Adjustment and Retraining in California with plans to cut 172 jobs at the company’s headquarters and U.S. field operations effective December 31, 2019.

Mallinckrodt Plc received a subpoena from the U.S. Securities and Exchange Commission for documents related to the drugmaker’s lawsuit against the U.S. Department of Health and Human Services (HHS).